Below is the version I would use as a 2026 evidence-based biofilm-treatment map.

Newer / Emerging Biofilm Treatments With Human Evidence

Approach	Biofilm target/mechanism	Human evidence	Current status
Bacteriophage therapy	Directly lyses susceptible bacteria; some phages penetrate/disrupt biofilm matrix	Multiple human studies, including randomized trials	Most important emerging technology
Customized phage cocktails	Matches phages to patient’s isolate; can combine multiple bacterial targets	Human chronic-wound RCT evidence	Investigational/compassionate depending jurisdiction
N-acetylcysteine (NAC)	Breaks disulfide bonds/mucus and can disrupt extracellular matrix; adjunct rather than standalone antimicrobial	Human RCT evidence in H. pylori; newer device-biofilm studies	Adjunct with disease-specific evidence
Alginate-disrupting therapy / OligoG	Modifies alginate-rich Pseudomonas biofilm and can enhance antibiotic activity	Human CF randomized trial	Investigational
Inhaled high-concentration antibiotics	Delivers very high local antibiotic concentrations into biofilm-containing airways	Extensive human RCT evidence in CF	Established for appropriate indications
Antimicrobial blue light (405–460 nm)	Generates ROS through endogenous bacterial chromophores	Human chronic-wound study; clinical development continuing	Emerging
Stabilized hypochlorous acid	Broad topical antimicrobial activity; targets wound bioburden/biofilm	First-in-human randomized trial	Emerging
Nitric-oxide releasing wound systems	NO damages microbial cells and can interfere with biofilm signaling/matrix	Human clinical development + earlier diabetic-ulcer trials	Emerging
Antibiofilm wound cleanser/gel systems	Chemical disruption + antimicrobial action against wound biofilm	Double-blind RCT in hard-to-heal wounds	Clinically available/emerging depending product
Anti-biofilm device coatings	Prevent/limit adhesion and biofilm development on implants/catheters	Extensive human device experience; new technologies in development	Established for selected devices; newer systems investigational
Photothermal / photodynamic nanotherapies	ROS and heat physically/chemically destroy biofilm	Mostly animal/in-vitro	Not established human treatment
Dispersin B	Enzymatically degrades PNAG biofilm matrix	Strong laboratory/animal evidence, but limited human therapeutic evidence	Investigational
DNase / eDNA disruption	Breaks extracellular DNA component of matrix	Human use exists for other indications; antibiofilm application remains disease-specific	Adjunct/investigational
Gallium	Mimics iron and interferes with bacterial iron metabolism/quorum signaling	Strong preclinical biofilm rationale; not established as general human biofilm therapy	Investigational
Engineered phages / phage-derived enzymes	Enhanced penetration, host range or matrix degradation	Mainly preclinical/early translational	Investigational

---

1. Bacteriophage therapy — probably the most important emerging category

Phages are particularly interesting because they can kill bacteria within biofilms without functioning like conventional antibiotics. They may also evolve/selection-pressure bacteria toward phenotypes that become more antibiotic-sensitive.

There is now meaningful human evidence rather than merely test-tube research.

The PhagoBurn randomized phase 1/2 trial evaluated a 12-phage cocktail against Pseudomonas aeruginosa burn-wound infection. The trial demonstrated feasibility and safety but did not demonstrate superiority, and the study was stopped because efficacy was insufficient. Importantly, the administered phage concentration was much lower than intended, illustrating one of the major practical problems with phage therapy.

More recently, a randomized placebo-controlled trial of customized bacteriophage cocktails in chronic wounds reported substantially better microbiological and healing outcomes in the phage arm. Thirty patients were assigned to each arm; conventional wound treatment was given to both groups, with customized phages added to the treatment arm.

The important point: this is not evidence that somebody should simply obtain a commercial phage preparation and self-treat. Phage therapy is highly dependent on the bacterial strain and requires appropriate microbiologic matching and clinical oversight.

Why I rank it so highly

It addresses several problems simultaneously:

• bacterial specificity
• antibiotic resistance
• biofilm-associated organisms
• potentially very high local concentrations
• possibility of combining phages with antibiotics
• possibility of engineering phages or adding matrix-degrading enzymes

A 2025 review of emerging therapies for difficult Gram-negative infections identifies phage therapy, anti-virulence approaches, antimicrobial peptides and immunotherapeutic approaches among the major emerging strategies entering human clinical use or trials.

References

Jault P, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019;19(1):35-45. PMID 30292481. DOI:10.1016/S1473-3099(18)30482-1.

• A Randomized, Placebo-controlled, Double-blind Clinical Trial of Bacteriophage Cocktails in Chronic Wound Infections.* PMID 38233034.

---

2. N-acetylcysteine — one of the more interesting matrix-disrupting adjuncts

NAC deserves more attention than simply calling it a “mucolytic.”

Its potential antibiofilm effects include:

• disrupting mucus/matrix structure
• affecting extracellular polymeric substances
• reducing bacterial adhesion
• improving antimicrobial penetration

There is actual human evidence.

A randomized trial in patients with repeatedly unsuccessful H. pylori eradication found that NAC pretreatment followed by culture-guided antibiotics produced eradication in 65% versus 20% without NAC. Biofilm persisted in the patients whose treatment failed.

There is also newer human evidence involving ureteral-stent biofilm prevention. A 2025 prospective randomized pilot study compared NAC with probiotics in 60 patients receiving ureteral stents.

However, this does not mean that oral NAC is a proven treatment for systemic or disseminated biofilm disease.

Key reference

Zullo A, et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol. 2010. PMID 20478402.

---

3. Alginate disruption — particularly interesting for Pseudomonas

This is a more specialized strategy.

Mucoid P. aeruginosa can produce large quantities of alginate, contributing to the protective matrix surrounding bacteria.

The idea is:

alginate disruption → improved antibiotic penetration → increased bacterial killing
Alginate lyases are particularly interesting because they enzymatically break down alginate.
However, I would not put alginate lyase into the established human-treatment category. Much of the impressive literature remains experimental.

One human-facing development is OligoG, an alginate oligosaccharide designed to modify the biofilm/mucus environment.
A randomized double-blind placebo-controlled crossover study evaluated inhaled OligoG in people with cystic fibrosis infected with Burkholderia cepacia complex. Fourteen subjects completed the study; OligoG produced reductions in bacterial counts, although the principal bacterial and lung-function outcomes did not reach statistical significance.

That makes OligoG interesting but not proven.

Important newer research

A 2024 study specifically evaluated whether alginate lyases remain functional under the elevated metal concentrations found in CF sputum. Several enzymes retained activity, strengthening the rationale for continued development.

References

Rye PD, et al. Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection. J Cyst Fibros. 2022. PMID 35086790. DOI:10.1016/j.jcf.2022.01.003.

Mahajan S, Ramya TNC. Cellulophaga algicola alginate lyase inhibits biofilm formation of a clinical Pseudomonas aeruginosa strain MCC 2081. IUBMB Life. 2021;73(2):444-462. PMID 33350564.

---

4. High-local-concentration inhaled antibiotics

This is less glamorous but considerably more clinically established.

For biofilm-associated Pseudomonas airway infection—particularly cystic fibrosis—inhaled antibiotics can achieve concentrations at the infection site that are difficult to obtain safely systemically.

Aztreonam lysine for inhalation is a good example.

Clinical trials demonstrate reductions in P. aeruginosa sputum density together with improvements in lung function and respiratory outcomes.

A randomized comparative trial involving 273 CF patients found inhaled aztreonam to produce better lung-function outcomes than inhaled tobramycin under the studied regimen.

A 2021 randomized crossover study also examined inhaled aztreonam plus IV colistimethate during acute exacerbations.
So this is a good example of a treatment that actually gets used in humans, while also exploiting one of the fundamental principles of biofilm treatment:

Get enough antimicrobial to the physical location of the biofilm.

---

5. Antimicrobial blue light — one of the most interesting non-antibiotic approaches

This deserves a prominent place in a 2026 list.

Blue light, particularly around 405–460 nm, can activate endogenous bacterial chromophores and generate reactive oxygen species.
Unlike conventional antibiotics, the mechanism is physical/photochemical.

A 2024 study examining high-intensity blue light against P. aeruginosa demonstrated activity against biofilms and a human skin-wound model. The investigators reported approximately 1.3–1.6-log reductions in bacterial numbers within biofilms and approximately 2.2-log reductions in the human wound model.

Even more importantly, a 2026 human chronic-wound study evaluated repeated 405-nm blue-LED treatments. Twenty-two patients received escalating doses; bacterial counts decreased in a dose-dependent fashion, with approximately 1.55-log reduction at 60 J/cm² and 1.82-log reduction at 100 J/cm² after the treatment series.

That’s much more interesting clinically than a purely in-vitro blue-light paper.

Combination approach

A 2025 study found that antimicrobial blue light could increase susceptibility of MRSA, P. aeruginosa and E. coli biofilms to tetracycline-class antibiotics.

References

High-Intensity Blue Light (450-460 nm) Phototherapy for Pseudomonas aeruginosa-Infected Wounds. Photobiomodul Photomed Laser Surg. 2024. PMID 38776546. DOI:10.1089/photob.2023.0180.

Pousty D, et al. Biofilm inactivation using LED systems emitting germicidal UV and antimicrobial blue light. Water Res. 2024;267:122449. PMID 39316962. DOI:10.1016/j.watres.2024.122449.

Blue LED Light Attenuates the Bacterial Bioburden in Chronic Wounds Transiently but Dose-Dependently. 2026. PMID 42388051.

---

6. Nitric oxide — very promising, but don’t confuse laboratory hydrogels with human treatment

NO has several potentially useful antimicrobial effects:

• membrane damage
• oxidative/nitrosative stress
• interference with quorum sensing
• biofilm dispersal
• modulation of wound healing

There has been human clinical investigation of NO-releasing wound systems, including randomized diabetic-foot-ulcer studies.
But many of the newest NO platforms are still preclinical biomaterials, such as self-healing hydrogels and nanomaterial systems.

Therefore:

NO = legitimate emerging biofilm technology

but

NO-releasing nanohydrogel = not yet routine human biofilm treatment.

---

7. Stabilized hypochlorous acid

This is much closer to real-world wound care.

A first-in-human randomized clinical study evaluated stabilized hypochlorous acid in patients with chronic leg ulcers.

This category is attractive because topical agents can directly contact the biofilm rather than depending on systemic penetration.
But again, the appropriate conclusion is:

topical wound antisepsis/bioburden reduction, not “systemically eradicates biofilm.”

---

8. New antibiofilm wound cleansers and gels

This category has actually reached randomized clinical testing.

A double-blind trial evaluated an antibiofilm cleanser/gel combination in hard-to-heal wounds. The study found a significant reduction in bacterial load, although the difference in achieving a 40% wound-area reduction did not reach statistical significance.

That is exactly the sort of evidence I would want to see before putting a wound product on a clinical biofilm-treatment list.

---

9. Dispersin B — scientifically fascinating, but not yet a routine human therapy

This is one of the most important biofilm-specific enzymes.

Dispersin B breaks down poly-N-acetylglucosamine (PNAG), a matrix polysaccharide used by many bacteria.

It can:

biofilm matrix → dispersin B → matrix degradation → bacterial exposure → antimicrobial killing

A major 2024 review summarizes almost 100 studies examining Dispersin B’s antibiofilm activity. It can detach established biofilms and increase susceptibility to antibiotics, antiseptics, phages and immune cells.

A particularly interesting 2025 experiment found that sequential Dispersin B → benzoyl peroxide treatment produced >6-log killing in a Cutibacterium acnes/Staphylococcus epidermidis biofilm model.

But:

I would NOT currently list systemic Dispersin B as a proven human treatment.

This is a good example of why we need to separate “biofilm science” from “human medicine.”

---

10. DNase / extracellular-DNA disruption

Extracellular DNA is another major component of many biofilm matrices.
DNase I can therefore act as a matrix-disrupting enzyme.
Experimental work demonstrates species-dependent effects: DNase I can detach S. aureus biofilm while Dispersin B may be more effective against S. epidermidis.
Recombinant human DNase I has also been shown experimentally to reduce staphylococcal biofilm and has obvious human-delivery advantages because recombinant DNase is already a clinically used biologic for other purposes.
But that does not establish systemic DNase as treatment for an arbitrary human biofilm infection.

---

11. Gallium — an especially interesting next-generation strategy

Gallium is fascinating because bacteria treat it somewhat like iron.

The concept is essentially:

bacterium wants iron → takes up gallium → gallium disrupts iron-dependent bacterial metabolism
Recent research has combined this concept with biofilm “awakening.”
A 2024 study described an aerosolized gallium-containing system designed to stimulate dormant P. aeruginosa in chronic lung biofilms, increasing metabolic activity and iron demand and thereby increasing gallium uptake.
Another 2024/2025 paper developed a gallium-containing nanosystem designed for sequential antibiofilm therapy.
Very interesting science.

But:

It is not currently an established human biofilm treatment.

I would put it in the next-generation research pipeline, not a treatment protocol.

---

12. Medical-device biofilms: the field is moving toward prevention + surface destruction

For catheters, implants, prostheses and other devices, simply giving another antibiotic may not solve the problem.
The emerging technologies include:

• antimicrobial surface coatings
• anti-adhesion surfaces
• nanostructured surfaces
• photothermal surfaces
• electrical stimulation
• surface-bound enzymes
• controlled-release antimicrobials

The FDA itself highlighted anti-biofilm technologies in a 2025 Grand Rounds presentation, including gold-nanorod photothermal ablation and electrical stimulation of biofilms.

FDA research has specifically investigated gold-nanorod-functionalized titanium surfaces that can produce bactericidal effects when exposed to near-infrared light.

These are exciting—but mostly device-development technologies, not something a patient receives as a conventional drug.

---

The treatments I would rank highest in 2026

If I were building a physician-facing shortlist, I’d divide them this way:

🟢 Most clinically credible

1. Surgical/debridement/source control
2. Culture-directed antimicrobial therapy
3. High-local-concentration/topical antimicrobial treatment where appropriate
4. Inhaled antibiotics for appropriate chronic airway infections
5. Antimicrobial wound cleansing/dressings
6. Selected medical-device antimicrobial technologies

🟡 Most promising emerging human technologies

1. Customized bacteriophage therapy
2. Phage + antibiotic combinations
3. Antimicrobial blue light
4. N-acetylcysteine as a disease-specific adjunct
5. OligoG/alginate-directed therapy
6. Nitric-oxide releasing systems
7. Stabilized hypochlorous-acid wound systems

🔴 Very promising but still predominantly experimental

1. Dispersin B
2. Alginate lyases
3. Gallium biofilm therapy
4. Engineered phages
5. Phage-derived depolymerases
6. DNase-based systemic antibiofilm therapy
7. Photothermal gold nanorods
8. Nanomotor/photothermal/NO combination systems
9. Quorum-sensing inhibitors
10. Anti-biofilm antimicrobial peptides
11. Biofilm-targeted nanoparticles

---

One very important correction to the way “biofilm treatment” is sometimes discussed

I would not construct a human treatment program around the assumption that a patient has one generalized biofilm throughout the body that can be “opened up” and then killed with a universal combination of NAC + enzymes + antibiotics + herbs.
Biofilms are ecological and anatomical phenomena. A Pseudomonas biofilm in a CF airway, S. aureus prosthetic-joint biofilm, dental plaque, chronic-wound biofilm and catheter-associated biofilm are fundamentally different therapeutic problems.
The FDA’s current work on device-associated biofilms likewise emphasizes that biofilm formation, antimicrobial resistance and the physical characteristics of the device all affect treatment.

The most exciting future model is therefore:

Identify organism(s)
↓
Identify anatomical biofilm niche
↓
Remove/debride/source-control where possible
↓
Break or bypass the matrix
↓
Apply organism-specific antimicrobial
↓
Use a second mechanism to prevent regrowth/resistance
That is where phages + antibiotics, matrix-degrading enzymes + antibiotics, light + antibiotics, and localized delivery + antimicrobial therapy become particularly interesting.
And this is why I would put customized bacteriophage therapy, antimicrobial blue light, matrix-disrupting agents, OligoG/alginate strategies, and targeted local delivery at the forefront of the 2026 biofilm-development landscape rather than treating supplements or broad “biofilm protocols” as equivalent.

Selected full-reference bibliography

 

1. Jault P, Leclerc T, Jennes S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019;19(1):35-45. PMID:30292481. DOI:10.1016/S1473-3099(18)30482-1.
2. A Randomized, Placebo-controlled, Double-blind Clinical Trial of Bacteriophage Cocktails in Chronic Wound Infections. PMID:38233034.
3. Zullo A, et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol. 2010. PMID:20478402.
4. Rye PD, et al. Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection. J Cyst Fibros. 2022. PMID:35086790. DOI:10.1016/j.jcf.2022.01.003.
5. Mahajan S, Ramya TNC. Cellulophaga algicola alginate lyase inhibits biofilm formation of a clinical Pseudomonas aeruginosa strain MCC 2081. IUBMB Life. 2021;73(2):444-462. PMID:33350564. DOI:10.1002/iub.2442.
6. Frost F, Young GR, Wright L, et al. The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: AZTEC-CF. J Cyst Fibros. 2021;20(6):994-1002. PMID:33358119. DOI:10.1016/j.jcf.2020.12.012.
7. Assael BM, et al. Inhaled aztreonam lysine vs inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros. 2013. PMID:22985692. DOI:10.1016/j.jcf.2012.07.006.
8. High-Intensity Blue Light (450-460 nm) Phototherapy for Pseudomonas aeruginosa-Infected Wounds.Photobiomodul Photomed Laser Surg. 2024. PMID:38776546. DOI:10.1089/photob.2023.0180.
9. Pousty D, Ma B, Mathews C, et al. Biofilm inactivation using LED systems emitting germicidal UV and antimicrobial blue light. Water Res. 2024;267:122449. PMID:39316962. DOI:10.1016/j.watres.2024.122449.
10. Blue LED Light Attenuates the Bacterial Bioburden in Chronic Wounds Transiently but Dose-Dependently. 2026. PMID:42388051.
11. Kaplan JB, et al. Synergistic activity of dispersin B and benzoyl peroxide against Cutibacterium acnes/Staphylococcus epidermidis dual-species biofilms. PLoS One. 2025. PMID:40146741.
12. Kaplan JB, et al. Aggregatibacter actinomycetemcomitans Dispersin B: The Quintessential Antibiofilm Enzyme. 2024. PMID:39204268.
13. A First-in-Human Randomized Clinical Study Investigating the Safety and Tolerability of Stabilized Hypochlorous Acid in Patients with Chronic Leg Ulcers.Wounds. 2024;13(11):529-541. PMID:38780759. DOI:10.1089/wound.2024.0040.
14. A double-blind trial comparing an antimicrobial combination to standard care in hard-to-heal wounds.J Wound Care. 2024;33(2):84. PMID:38329833. DOI:10.12968/jowc.2024.33.2.84.
15. Wake biofilm up to enhance suicidal uptake of gallium for chronic lung infection treatment.Biomaterials. 2024. PMID:38805955. DOI:10.1016/j.biomaterials.2024.122619.
16. Guo Z, Ge M, Ruan Z, et al. 2D Janus carrier-enabled Trojan horse: Gallium delivery for the sequential therapy of biofilm associated infection. Biomaterials. 2025;313:122761. PMID:39241550. DOI:10.1016/j.biomaterials.2024.122761.
17. Efficacy and safety of N-acetylcysteine vs. probiotics in in-vivo biofilm prevention on ureteral stents: a prospective randomized controlled pilot in vivo study. 2025. PMID:40788469. DOI:10.1007/s11255-025-04713-w.

Bottom line: If your goal is specifically to identify the newest biofilm treatments that have crossed from laboratory research into actual human use, I would focus first on phage therapy, antimicrobial blue light, NAC as a targeted adjunct, alginate/OligoG approaches, NO systems, advanced wound antibiofilm products, and device-directed antibiofilm technologies. Gallium, Dispersin B, engineered phages, alginate lyases and nanomaterial therapies are exciting next-generation candidates but should not yet be presented as established human treatments.